Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Metropolis Healthcare's Enterprise Value is ₹120,377 Mil.
Metropolis Healthcare's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil. Therefore, Metropolis Healthcare's EV-to-FCF for today is .
The historical rank and industry rank for Metropolis Healthcare's EV-to-FCF or its related term are showing as below:
NSE:METROPOLIS'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 40.19
Current: 40.19
During the past 11 years, the highest EV-to-FCF of Metropolis Healthcare was 40.19. The lowest was 0.00. And the median was 0.00.
NSE:METROPOLIS's EV-to-FCF is ranked worse than 70% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.65
vs NSE:METROPOLIS: 40.19
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Metropolis Healthcare's PE Ratio (TTM) for today is calculated as:
Metropolis Healthcare's share price for today is ₹576.75.
Metropolis Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹9.708.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's EV-to-FCF falls into.
Metropolis Healthcare's current Enterprise Value is ₹120,377 Mil.
Metropolis Healthcare's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹576.75 is trading 3.6% below its estimated GF Value™ of ₹598.37.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
EV-to-FCF:
GF Value™: ₹598.37 vs. price of ₹576.75 (3.6% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
